Renovaro Inc.

Equities

RENB

US29350E1047

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.53 ^USD	-10.00%		-29.49%	-51.74%

Apr. 24	Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	MT
Apr. 18	Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	CI

Renovaro Biosciences Inc. Reports Earnings Results for the Full Year Ended June 30, 2023

October 02, 2023 at 07:31 am EDT

Renovaro Biosciences Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was USD 39.68 million compared to USD 113.43 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 2.16 a year ago.

Latest news about Renovaro Inc.

Renovaro's RenovaroCube Amends Agreement to Acquire 100% Stake in Cyclomics	Apr. 24	MT
Renovaro Inc. Announces Geert Kazemier, MD, PhD, as the New Chairman of its Scientific Advisory Board	Apr. 18	CI
Renovaro Inc. Appoints Simon Tarsh as Interim Chief Financial Officer	Mar. 13	CI
Renovaro Inc. Announces Resignation of Luisa Puche as Chief Financial Officer, Effective as of March 21, 2024	Mar. 05	CI
Renovaro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Renovaro Inc. Announces Board Changes	Feb. 14	CI
Sector Update: Health Care Stocks Gain Late Afternoon	Feb. 14	MT
Sector Update: Health Care	Feb. 14	MT
Renovaro Shares Jump After Response to Short Seller Hindenburg's Report	Feb. 14	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 13	MT
Renovaro's GEDi Cube Agrees to Acquire 75% Stake in Cyclomics	Feb. 13	MT
Renovaro Shares Tumble Following Report From Short-Seller Hindenburg	Feb. 13	MT
Renovaro Biosciences Inc. completed the acquisition of GEDi Cube Intl Ltd.	Feb. 12	CI
Top Premarket Gainers	Feb. 07	MT
Renovaro Biosciences' Shareholders Approve Share Issuance for Merger Deal With GEDi Cube	Jan. 25	MT
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Renovaro Biosciences Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Renovaro Biosciences Inc. Appoints Avram Miller as Board of Directors	23-10-11	CI
Renovaro Biosciences Inc. Appoints Leni Boeren and Ruud Hendriks as Independent Directors	23-10-10	CI
North American Morning Briefing : Stock Futures, -2-	23-10-05	DJ
Renovaro Biosciences Inc. announced that it expects to receive $2 million in funding	23-10-04	CI
Renovaro Biosciences Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-02	CI
Sector Update: Health Care Stocks Declining Friday Afternoon	23-09-29	MT
Renovaro Biosciences, GEDi Cube Enter Stock-for-stock Acquisition Deal	23-09-29	MT
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ

Chart Renovaro Inc.

Duration

Period

More charts

Company Profile

Renovaro Inc., formerly Renovaro BioSciences Inc., is a biotechnology company. The Company is engaged in the research and development of pharmaceutical and biological products for the treatment of cancer, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. The Company has a single product candidate as a potential cure for HIV, RENB-HV01, adding two additional pipeline candidates for HIV, RENB-HV12 and RENB-HV21, a pipeline for HBV, RENB-HB01, and with a significant into cancer immune therapies to address high unmet needs from difficult-to-treat solid tumors, RENB-DC11. RENB-HV-01 is a HIV autologous transplant with genetically modified cells. RENB-HV12 is a HIV therapeutic vaccine for potential long-term remission/cure. RENB-HV-21, a treatment for HIV with allogenic Natural Killer (NK) and Gamma Delta T-Cells (GDT). RENB-HB-01 is an HBV gene therapy candidate.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVARO INC.	-51.74%	220M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs